IgA Nephropathy – Pipeline Analysis, Clinical Trials & Results, 2017

IgA Nephropathy Pipeline

The study analyzed that the IgA nephropathy pipeline comprises of 12 drug candidates in different stages of development. IgA nephropathy, also known as Berger’s disease, is a kidney disorder that occurs when IgA antibody gets settled in the kidneys. This leads to inflammation that with time hinders the kidney’s ability to filter wastes from blood. IgA nephropathy is a silent disease in its early stages with no symptoms. But the most common symptoms that are usually observed are proteinuria and hematuria. IgA nephropathy does not have a specific treatment, and the only treatment available is to delay or prevent end stage renal disease (ESRD). Therefore, combination therapies are being used to slow down the rate of proteinuria and hematuria and the use of various targets including a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS) is expected to provide an effective and concrete treatment for the disease, with latest technological advancements further adding to the pipeline growth.

Pharmalink AB is using TARGIT drug delivery technology platform for the development of Budesonide for IgA nephropathy. The TARGIT technology is based on the application of a combination of enteric polymers onto injection-moulded starch capsules, for the targeted delivery of drugs to specific regions of the large intestine.

Some of the key players developing drugs for IgA nephropathy include Mallinckrodt plc, Merck KGaA, Anthera Pharmaceuticals, Inc. and others.

News Courtesy : P&S Market Research


Glaucoma Therapeutics Market – Research Report, Analysis, 2023

Glaucoma Therapeutics MarketOcular hypertension is one of the major causes due to which glaucoma occurs in patients. Glaucoma mostly occurs at the age over 40, but it may also occur in children, young adults, and infants. Diagnosis of glaucoma can be done through a simple eye examination with the help of tonometry, an instrument used for measuring intraocular pressure, by an ophthalmologists and optometrist. Prevention of glaucoma is difficult; however, if diagnosed and treated at an early stage, the disease can be controlled by using eye drops prescribed by doctor, microsurgery or by laser surgery. Glaucoma can damage the vision of the affected eye permanently; in first stage it decreases the peripheral vision and if not treated, it can lead to blindness.

For more information visit: https://www.psmarketresearch.com/market-analysis/glaucoma-therapeutics-market

The global glaucoma therapeutics market can be divided into two types based on the factor that the disease is known or not. A known disease called as open angle and the not known disease is closed angle glaucoma.  Open angle glaucoma is painless and tends to develop slowly over time, with no symptoms until the disease progress to a considerable extent. Whereas, closed angle glaucoma is characterized by redness in eye, sudden eye pain, vomiting and various other symptoms and it should be treated immediately. On the basis of treatment used to cure the disease, the global glaucoma therapeutics market can be categorized as beta blockers, prostaglandins, carbonic anhydrase inhibitors, alpha adrenergic agonists, and fixed dose combinations.

Increase in awareness of glaucoma, medicare coverage of glaucoma patients and demand for combination glaucoma drugs are some of the major trends that can be seen in global glaucoma therapeutics market.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/glaucoma-therapeutics-market/report-sample

Some of the major competitors in global glaucoma therapeutics market are Pfizer Inc., Allergen Inc., Novartis A.G., Merck & Co. Inc., Aerie Pharmaceuticals Inc., Inotek Pharmaceuticals Corp., Carl Zeiss Meditec Inc., Acadia Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., NicOx SA, Santen Pharmaceuticals Co. Ltd., Otsuka Holdings Co. Ltd., SIFI SpA, and Valeant Pharmaceuticals International Inc.

Pain Management Drugs Market Analysis, Growth and Forecast to 2023

Pain Management Drugs Market

The growing geriatric population and increasing demand of innovative and advanced pain relaxing medications around the world are the predominant growth drivers for the global pain management drugs market. Additionally, the increasing number of hospitalization cases; unmet requirements for neuropathic pain management drugs; innovative and advanced applications of pain management therapies; increasing prevalence of various chronic diseases, such as cancer, and neurological problems; and increasing healthcare expenditure are also driving the growth of the global market. The growing numbers of mergers and acquisitions is a key trend observed in the market. Among the various therapeutic indications, the post-operative pain relief segment accounted for the largest share, and the low-back pain segment accounted for the second largest share in the global market.

Explore Report at: https://www.psmarketresearch.com/market-analysis/pain-management-drugs-market

Pain management drugs are mainly used to relieve discomfort associated with injury and surgeries. Moreover, pain management medications are used in the management of pain associated with neurological problems, migraine, cancer, orthopedic problems, low- back pain, rheumatoid arthritis, and fibromyalgia.

North America and Europe are the major markets, due to increasing prevalence of chronic diseases, and growing awareness about various types of chronic pain conditions in these regions. The U.S. followed by Canada, is the largest market for pain management drugs in North America. Whereas, the U.K., Germany and France are some of the major countries holding significant share in the European pain management drugs market.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/pain-management-drugs-market/toc-sample

The Asian market is growing with a significant rate, owing to huge pool of patients, and increasing healthcare spending in the region. In addition, the initiatives taken by various government associations to develop chronic pain rehabilitation centers, and increasing prevalence of various chronic diseases are also supporting the growth of the Asian pain management drugs market. The countries such as India, Japan and China, are the major markets in the region.

Some of the major players operating in the global pain management drugs market include Purdue Pharma L.P., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Forest Laboratories Inc., Endo International PLC, Johnson & Johnson, Pfizer Inc., Valeant Pharmaceuticals International Inc., GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd., and Baxter International Inc.

Graft Versus Host Disease Treatment Market Pipeline Analysis, Growth and Forecast to 2023

Graft Versus Host Disease Treatment MarketThe global graft versus host disease (GVHD) treatment market is expected to witness considerable growth due to increasing number of hematopoietic stem cell transplantations (HSCTs), advancement in technologies, and increasing collaboration among the pharmaceutical companies. The regulatory bodies are supporting the graft versus host disease market by providing designations and grants for speeding up the drug development process. Currently, there are more than 15 targets, which are being used for the treatment of GVHD including T lymphocytes, OX40, Bruton’s tyrosine kinase, Toll-like receptors, tumor necrosis factor alpha, neutrophil elastase, and several B and T lymphocytes. Some of the companies use their own technologies for the development of drugs for graft versus host disease such as Bellicum Pharmaceuticals, Inc. and Targazyme, Inc.  Bellicum Pharmaceuticals, Inc. is using CaspaCIDe technology and Targazyme, Inc. is using Fucosylation technology.

Explore Report at: https://www.psmarketresearch.com/market-analysis/gvhd-treatment-market

The pipeline of GVHD is very rich with more than 60 drugs. Top pharmaceutical companies such as Dr. Falk Pharma GmbH and Mallinckrodt plc are expected to launch their products in coming years, as the products are in Phase III stage of development. The therapeutics involved in the treatment of GVHD comprise different molecule types including antibody drug conjugate, antibodies, cell therapy, monoclonal antibodies and recombinant proteins.

Geographically, North America was the largest market for GVHD treatment in 2015, owing to the high incidence of HSCTs, high healthcare expenditure and large number of research and development activities. The U.S. contributed largest revenue to the North American GVHD treatment market and it is expected to remain the largest market globally, during the forecast period.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/gvhd-treatment-market/toc-sample

Some of the key players operating in the global market are Dr. Falk Pharma GmbH, Mallinckrodt Pharmaceuticals, Apceth GmbH & Co. KG, Targazyme Inc., Bellicum Pharmaceuticals, Inc., Cellect Biotechnology Ltd., Sanofi, Novartis AG, Gilead Sciences, Inc., AbbVie Inc., and Takeda Pharmaceutical Company Ltd.

mTOR Inhibitors Market Pipeline Analysis, Growth and Forecast to 2023

mTOR Inhibitors Market

The global mammalian target of rapamycin (mTOR) inhibitors market is witnessing considerable growth due to their application in several therapeutic areas such as cancer, renal dysfunction and eye disorders. The regulatory bodies are providing funding and designation to the drug candidates for advancement of their products. Moreover, the increasing awareness related to the effective use of mTOR inhibitors, in combination with chemotherapy and its implications in cancer therapy is also supporting the growth of global market. Different classification of mTOR inhibitors and their unique features is leading to their increased demand. Among the different generations of mTOR inhibitors, third generation mTOR inhibitors exploit the unique juxtaposition of two drug-binding pockets to create a bivalent interaction that allows inhibition of resistant mutants.

Explore Report at: https://www.psmarketresearch.com/market-analysis/mtor-inhibitors-market

The involvement of antibiotics and proteins for drug development and technological advancements for mTOR inhibitors are expected to create ample growth opportunities for the global market. However, high cost of the marketed drugs and complexity in understanding the mechanism of action are the limitations associated with mTOR inhibitors, which are hampering the growth of the global market.

Geographically, North America was the largest market for mTOR inhibitors in 2015, owing to the large number of research and development activities, high healthcare expenditure, and high prevalence of chronic diseases such as cancer and cardiovascular diseases. The U.S. contributed largest revenue to the North American mTOR inhibitors market and it is expected to remain the largest market globally, during the forecast period. The supporting government regulations taken by the federal government is the key driving factor of the U.S. mTOR inhibitors market.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/mtor-inhibitors-market/toc-sample

The key players operating in the global market are Pfizer Inc., Novartis AG, AstraZeneca plc, Eli Lilly and Company, Ability Pharma, GlaxoSmithKline, MEI Pharma, Verastem, Inc., Phusis Therapeutics, Inc., and Co-D Therapeutics, Inc.

Hepcidin antagonist, Pipeline Analysis, 2017

The hepcidin antagonist pipeline has more than 10 drugs. In pipeline analysis, drugs are analyzed on the basis of route of administration and molecule type. The pipeline is also analyzed on the basis of monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Pre-clinical stage.

Explore Report at: https://www.psmarketresearch.com/market-analysis/hepcidin-antagonist-pipeline-analysis

Phase III

Phase III clinical trial known for the comparison of new treatments with the standard treatment in which the safety, efficacy and side effects of new intervention is compared with the already existing treatment. The Phase III clinical trial takes around 2-3 years to complete and the total number of participants vary from 100-1,000. In Hepcidin antagonist, there are 3 drugs in phase III clinical trial. For instance, Luspatercept, a phase III drug candidate of Celgene Corporation is being developed in collaboration with Acceleron Pharma, Inc., for the treatment of anemia with myelodysplastic syndromes and anemia associated with beta thalassaemia.

Phase II

NOX-H94 is a phase II drug candidate of NOXXON Pharma N.V. The drug candidate is an anti-hepcidin single-stranded structured L-RNA oligonucleotide conjugated to 40kDa polyethylene glycol. Phase II clinical trial is the second phase that answer safety, efficacy and dosing of the new intervention. It takes around 2 years to complete and between 100 – 120 patients participate in the Phase II trial.

Phase I

PRS 080, a phase I/II drug candidate is under development by Pieris Pharmaceuticals, Inc. for the treatment of anemia. The drug candidate is an hepcidin antagonist, which can restore iron utilization and erythropoiesis.  The company mentioned that the compound has successfully shown a favorable safety profile in healthy volunteers and is expected to complete a multi-dose trial by mid of 2017. In Phase I clinical trial, safety of the new intervention is determined. The trial takes around 1-2 years to complete and the total number of volunteers participating in the trial vary between 15 – 30.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/hepcidin-antagonist-pipeline-analysis/report-sample


Pipeline analysis provides description about the key companies developing hepcidin antagonist drugs. Some of the key players actively involved in the research and development are Celgene Corporation, Akebia Therapeutics, Inc., FibroGen, Inc., Noxxon Pharma AG and Tolero Pharmaceuticals, Inc.

Janus Kinase Inhibitors Pipeline Analysis – Designation, Collaboration and Developments

Janus kinase (JAK) inhibitors block Janus kinase activator enzymes and interrupt signaling pathway. It plays an important role in host defense, oncology, autoimmunity and hematological cancers, which makes them an important target for therapeutics. Many signal transduction pathways are done by JAK activity for the normal signaling. The abnormal aberration in JAKs activity can lead to diseased state. For instance, over activation of JAK can lead to tumorigenesis whereas loss of JAK can lead to severe combined immunodeficiency. Janus Kinases family contains JAK 1, JAK 2, JAK 3 and a group of cytoplasmic non-receptor Tyrosine kinases (NRTKs).

Explore Report at: https://www.psmarketresearch.com/market-analysis/janus-kinase-inhibitors-pipeline-analysis

The cytokine receptor is associated with JAKs present on the surface of cells. JAK tyrosine kinase family are primarily associated with signal transduction originating from extracellular ligands, which often interact with transmembrane receptors. Different JAK tyrosine kinase are the key components in mediating signaling process such as expression of genes involved in proliferation, apoptosis, migration, and differentiation. They play a major role in immune defense as many signaling events involved in both innate and adaptive immunity is mediated by JAKs. They are also involved in cell growth, survival, development, and differentiation of immune cells. Mutation in JAKs leads to the immunodeficiency disorders.

Aclaris Therapeutics, Inc. is developing ATI-50001, a pre-clinical drug candidate for the treatment of alopecia universalis and alopecia totalis. Pre-clinical study is also known as animal study. It is done before testing a drug in people to find out the toxicity profile of the drug. Pre-Clinical study is of two types, including In vitro and In vivo.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/janus-kinase-inhibitors-pipeline-analysis/report-sample

Pipeline analysis provides description about the key companies developing JAK inhibitor drugs. Some of the key players actively involved in the research and development are Galapagos NV, AbbVie Inc., Eli Lilly and Company, Gilead Sciences, Inc., Astellas Pharma Inc., CTI BioPharma Corp., Portola Pharmaceuticals, Inc., Japan Tobacco International, Incyte Corporation, Pfizer, Inc., and Asana BioSciences, LLC.

Hodgkin’s Lymphoma Therapeutics Pipeline Analysis 2017

Hodgkin_s Lymphoma Therapeutics Pipeline

The Hodgkin’s lymphoma therapeutics pipeline is expected to witness considerable growth in the coming years as the researchers are making novel drug delivery system for the treatment for cancer. The government agencies such as National Cancer Institute and American Cancer Society are supporting the growth of the Hodgkin’s lymphoma (HL) therapeutics pipeline by providing funding, designations and grants for speeding up the drug development process. High prevalence of cancer, increasing awareness regarding cancer treatment, technological advancements and high demand for safe and effective medication are driving the growth of the Hodgkin’s Lymphoma therapeutics pipeline.

Explore Report at: https://www.psmarketresearch.com/market-analysis/hodgkins-lymphoma-therapeutics-pipeline-analysis

Hodgkin lymphoma (HL) or Hodgkin’s disease is an uncommon cancer of the lymphatic system, such as lymph nodes. The lymphatic system is made up of a network of vessels and glands that spread throughout the body. The vessels of lymphatic system known as lymphocytes carrying clear fluid known as lymph, contains lymphocytes (white blood cells that help combat infection). The lymphatic is a part of the human body’s immune system. In Hodgkin’s lymphoma, the patient experiences a painless swelling in a lymph node, usually in the neck, armpit or groin.

Pharmaceutical companies, such as Mirati Therapeutics, Inc., are developing Mocetinostat in combination with Brentuximab Vedotin in Phase I/II stage for Hodgkin’s lymphoma. Mocetinostat is an orally bioavailable and spectrum-selective Histone Deacetylase (HDAC) inhibitors. The drug candidate is believed to reverse aberrant acetylation resulting from histone acetyltransferase (HAT) mutations, thereby prohibiting tumor progression and reducing tumor burden in patients.

According to the National Cancer Institute, a part of the U.S. National Institutes of Health, an estimated 8,500 new cases and 1,120 deaths were reported in the U.S., in 2016, due to Hodgkin’s lymphoma.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/hodgkins-lymphoma-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of Hodgkin’s lymphoma therapeutics include Bristol-Myers Squibb Co., Merck & Co. Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Affimed Therapeutics AG, Aeterna Zentaris Inc., Incyte Corporation, and 4SC AG.

Multiple Myeloma Therapeutics Pipeline – Patent, Collaboration and Other Developments

Multiple Myeloma (MM) Therapeutics Pipeline

The multiple myeloma therapeutics pipeline is expected to witness considerable growth in the coming year due to high prevalence of the disease. The growth of multiple myeloma therapeutics pipeline is assisted by targeted therapy and new effective treatment. Also, increased awareness among the population about the various cancer treatments has further fueled the growth of the therapeutics pipeline. Increasing healthcare expenditure and technological advancements are supporting the growth of the therapeutics pipeline for multiple myeloma. An increasing demand for safe and effective medications is also driving the growth of the multiple myeloma therapeutics pipeline. Many government initiatives such as increased funding, designations and grants for speeding up the drug development process has also supported the growth of the therapeutics pipeline.

Explore Report at: https://www.psmarketresearch.com/market-analysis/multiple-myeloma-therapeutics-pipeline-analysis

The National Cancer Institute, which is a part of the U.S. National Institutes of Health, defines multiple myeloma as a cancer that is formed by malignant plasma cells. Normal plasma cells are found in the bone marrow as an important part of the immune system. The immune system is made up of several types of cells that work together to fight infections and other diseases. Lymphocytes (lymph cells) are the main cell types of the human immune system and the major types of lymphocytes are T cells and B cells. When B cells respond to an infection, they mature and change into plasma cells. Plasma cells make the antibodies (also known as immunoglobulins) that help the body attack and kill germs. Lymphocytes are present in many areas of the body, such as lymph nodes, bone marrow, intestines, and the bloodstream. Plasma cells, however, are mainly found in the bone marrow. Bone marrow is the soft tissue found inside some hollow bones. In addition to plasma cells, the bone marrow has those cells that make the different normal blood cells.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/multiple-myeloma-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of myeloma therapeutics include Celgene Corporation, Bristol-Myers Squibb, Abbvie, Inc., Novartis AG, F. Hoffman La Roche AG, Amgen, Inc., Karyopharm Therapeutics, Inc., Array BioPharma, and Takeda Pharmaceutical Company Limited.

Thyroid Cancer Therapeutics Pipeline – Clinical Trials & Results, Patent and Developments

Thyroid Cancer Therapeutics Pipeline

The thyroid cancer therapeutics pipeline is expected to witness considerable growth due to increase in the demand for the targeted drug formulation for the treatment of cancer. Though less number of drugs are available for thyroid cancer treatment, an increasing awareness regarding cancer treatment and high demand for safe and effective medications are driving the therapeutics pipeline.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/thyroid-cancer-therapeutics-pipeline-analysis/toc-sample

According to the National Cancer Institute, a part of the U.S. National Institutes of Health, thyroid cancer is a rare type of cancer that affects the thyroid gland, a small gland at the base of the neck that produces hormones. It most commonly occurs in people aged 30-year-old. Women are two to three times more likely to develop this thyroid cancer, as compared to men. Thyroid cancer is usually treatable, and in many cases, can be cured completely, although it can sometimes come back after treatment. There are four main types of thyroid cancer; papillary thyroid cancer, follicular thyroid cancer (hurthle cell thyroid cancer), medullary thyroid cancer and anaplastic thyroid cancer.

Among the presently available drugs, Lenvatinib, a small molecule drug candidate of Eisai Co Ltd., was approved by USFDA on 13 February 2015. It is an orally active multi-targeted kinase inhibitor, which inhibits vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptors and other tyrosine kinases.

Pre-Purchase Enquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=thyroid-cancer-therapeutics-pipeline-analysis

Many pharmaceutical companies are focusing on the research and development of thyroid cancer therapeutics pipeline drug candidates, collaborating with one another. In February 2015, Biologics, Inc., an integrated oncology services company, reported that it was selected by Eisai Co. Ltd. as a specialty pharmacy provider within Eisai’s limited distribution network for Lenvima (lenvatinib).

Some of the key players having a pipeline of thyroid cancer therapeutics include Eisai & Co. Ltd., Exelixis, Amgen, AstraZeneca plc, Merck & Co., Inc., Daiichi Sankyo Company Limited, and F. Hoffmann-La Roche AG.